カテゴリー: COVID-19

🔥Bản Tin Mới Nhất Covid-19 Trưa 15/9 | Thông Tin Khẩn Từ Bộ Y Tế | Tin Tức 24h
—————————————————–
Xem thêm thông tin chi tiết tại: https://youtube.com/playlist?list=PLayRHQCsjlU8k9ShfxkrPJ8xjwlOeffaA
Đăng ký kênh: https://www.youtube.com/channel/UCrXTLKK7xUEWB7BHV2fyBdw
Facebook: https://www.facebook.com/tt24hnews/
Kênh Tin Tức 24h liên tục cập nhật các tin tức mới nhất trong ngày
#tintuc24h #tintuc24htv #tinmoinhat #tintucmoi #news #tt24h

Het COVID-19 Journaal is een verslag, waarin u wordt geïnformeerd over de meest recente ontwikkelingen in de strijd tegen het COVID-19 virus. Dit programma is een productie van het ministerie van Volksgezondheid en verschijnt van maandag tot en met vrijdag.

Watch Akshay Kumar, the brand ambassador of Mylab Discovery Solutions Pvt Ltd explaining the usage of the CoviSelf™ kit..

Mylab’s CoviSelf™ test kit advertisement to understand the usage of the kit.

KEI hosted a virtual roundtable to discuss pathways to scale production, increase competition and speed the delivery of COVID-19 vaccines. Experts and policymakers exchanged views on the challenges and opportunities to scale production of COVID-19 vaccines. In this dialogue, experts addressed practical issues for the transfer of know-how and technology for manufacturing.

Questions and topics that were raised include:

1. Which vaccines represent the most significant opportunities in terms of scaling manufacturing capacity and enhancing access?

06:47 – Ingrid Kromann (CEPI)
10:45 – Alain Alsahani (MSF)
16:12 – Amine Kamen (McGill University)
19:23 – Fabrizio Chiodo (Italian National Research Council)
25:32 – James Krellenstein (Prep4All)

2. What incentives, mandates and/or subsidies are useful in expanding access to vaccine manufacturing know-how and capacity?

31:11 – James Love (KEI)
39:03 – Mariângela Simão (WHO)
48:26 – Kevin McCarthy (European Commission)

3. What is currently known about global manufacturing capacity for each relevant COVID-19 vaccine, and what measures are necessary to bring a facility into good manufacturing practice compliance for production of specific vaccines and other COVID-19 health technologies?

58:23 – Edward Hammond (independent consultant)
1:04:13 – Kris Howard (NRL Enterprise Solutions)
1:11:23 – Martin Friede (WHO)
1:15:50 – Fred Abbott (Florida State University)
1:20:48 – Tertia Bailey (Manufacturing Africa Adviser for Senegal and Cote d’Ivoire)
1:25:02 – KM Gopakumar (Third World Network)

4. What is the WHO prequalification program doing regarding COVID-19 vaccines?

5. What is the WHO C-TAP doing to expand manufacturing for COVID-19 vaccines?

1:29:48 – Erika Dueñas Loayza (WHO)

6. What is the Medicines Patent Pool doing to expand manufacturing for COVID-19 vaccines?

1:35:48 – Charles Gore (MPP)

7. What are national governments doing to scale and expand vaccine manufacturing access?

01:51:07 – Arianna Schouten (KEI)

8. What mistakes were made in 2020, and what mistakes need to be avoided in 2021?

01:54:13 – Peter Singer (WHO)
01:58:42 – Mohga Kamal-Yanni (senior advisor to the People’s Vaccine Alliance)
02:03:00 – Ellen ‘t Hoen (ML&P)
02:07:22 – Manuel Martin (MSF)
02:11:28 – Brook Baker (Health GAP)

Additional resources: https://www.keionline.org/covid-19-vaccine-manufacturing-capacity

KEI is also hosting an email list to share information, resources and news on these issues. To join the public, archived list, please visit: http://lists.keionline.org/mailman/listinfo/vaccine-manufacturing_lists.keionline.org